Clinical Trial: Canakinumab for Treatment of Adult Onset Still's Disease

Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional

Official Title: Canakinumab for Treatment of Adult Onset Still's Disease to Achieve Reduction of Arthritic Manifestation

Brief Summary: Interleukin-1 antagonists such as canakinumab have been used for the treatment of AOSD and have had a marked influence on the activity of the disease, including joint mobility. Results from controlled clinical studies are not, however, currently available.

Detailed Summary:
Sponsor: Charite University, Berlin, Germany

Current Primary Outcome: Efficacy of canakinumab with a clinically-significant reduction in disease activity [ Time Frame: 12 weeks ]

Investigation of the efficacy of canakinumab in patients with AOSD and active joint involvement in terms of the proportion of patients with a clinically-significant reduction in disease activity (DAS28 > 1.2) following a treatment period of 12 weeks.


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Charite University, Berlin, Germany

Dates:
Date Received: July 29, 2014
Date Started: June 2012
Date Completion: August 2017
Last Updated: July 25, 2016
Last Verified: July 2016